Erratum: Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis (Journal of Hepatology (2019) 70(5) (930–940), (S0168827819300297), (10.1016/j.jhep.2018.12.038))

Taesik Gwag; Zhaojie Meng; Yipeng Sui; Robert N. Helsley; Se Hyung Park; Shuxia Wang; Richard N. Greenberg; Changcheng Zhou

doi:10.1016/j.jhep.2021.01.003

Erratum: Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis (Journal of Hepatology (2019) 70(5) (930–940), (S0168827819300297), (10.1016/j.jhep.2018.12.038))

Taesik Gwag, Zhaojie Meng, Yipeng Sui, Robert N. Helsley, Se Hyung Park, Shuxia Wang, Richard N. Greenberg, Changcheng Zhou

Research output: Contribution to journal › Comment/debate

Abstract

It has come to our attention that there was a mistake in Fig. 6 in the published version of our manuscript. The mistake occurred during the publication process and has resulted in the labelling being inverted for the treatments with emtricitabine and efavirenz in the graph in Fig. 6A. Please see the corrected figure above. We apologize for any inconvenience caused.

Original language	English
Pages (from-to)	1003-1004
Number of pages	2
Journal	Journal of Hepatology
Volume	74
Issue number	4
DOIs	https://doi.org/10.1016/j.jhep.2021.01.003
State	Published - Apr 2021

Bibliographical note

Publisher Copyright:
© 2019 European Association for the Study of the Liver

ASJC Scopus subject areas

Hepatology

Access to Document

10.1016/j.jhep.2021.01.003

Fingerprint

Dive into the research topics of 'Erratum: Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis (Journal of Hepatology (2019) 70(5) (930–940), (S0168827819300297), (10.1016/j.jhep.2018.12.038))'. Together they form a unique fingerprint.

Cite this

Gwag, T., Meng, Z., Sui, Y., Helsley, R. N., Park, S. H., Wang, S., Greenberg, R. N., & Zhou, C. (2021). Erratum: Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis (Journal of Hepatology (2019) 70(5) (930–940), (S0168827819300297), (10.1016/j.jhep.2018.12.038)). Journal of Hepatology, 74(4), 1003-1004. https://doi.org/10.1016/j.jhep.2021.01.003

@article{378d6c7fe39048e0846ed21388edaa1e,

title = "Erratum: Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis (Journal of Hepatology (2019) 70(5) (930–940), (S0168827819300297), (10.1016/j.jhep.2018.12.038))",

abstract = "It has come to our attention that there was a mistake in Fig. 6 in the published version of our manuscript. The mistake occurred during the publication process and has resulted in the labelling being inverted for the treatments with emtricitabine and efavirenz in the graph in Fig. 6A. Please see the corrected figure above. We apologize for any inconvenience caused.",

author = "Taesik Gwag and Zhaojie Meng and Yipeng Sui and Helsley, {Robert N.} and Park, {Se Hyung} and Shuxia Wang and Greenberg, {Richard N.} and Changcheng Zhou",

note = "Publisher Copyright: {\textcopyright} 2019 European Association for the Study of the Liver",

year = "2021",

month = apr,

doi = "10.1016/j.jhep.2021.01.003",

language = "English",

volume = "74",

pages = "1003--1004",

number = "4",

}

Gwag, T, Meng, Z, Sui, Y, Helsley, RN, Park, SH, Wang, S , Greenberg, RN & Zhou, C 2021, 'Erratum: Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis (Journal of Hepatology (2019) 70(5) (930–940), (S0168827819300297), (10.1016/j.jhep.2018.12.038))', Journal of Hepatology, vol. 74, no. 4, pp. 1003-1004. https://doi.org/10.1016/j.jhep.2021.01.003

Erratum: Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis (Journal of Hepatology (2019) 70(5) (930–940), (S0168827819300297), (10.1016/j.jhep.2018.12.038)). / Gwag, Taesik; Meng, Zhaojie; Sui, Yipeng et al.
In: Journal of Hepatology, Vol. 74, No. 4, 04.2021, p. 1003-1004.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Erratum

T2 - Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis (Journal of Hepatology (2019) 70(5) (930–940), (S0168827819300297), (10.1016/j.jhep.2018.12.038))

AU - Gwag, Taesik

AU - Meng, Zhaojie

AU - Sui, Yipeng

AU - Helsley, Robert N.

AU - Park, Se Hyung

AU - Wang, Shuxia

AU - Greenberg, Richard N.

AU - Zhou, Changcheng

PY - 2021/4

Y1 - 2021/4

N2 - It has come to our attention that there was a mistake in Fig. 6 in the published version of our manuscript. The mistake occurred during the publication process and has resulted in the labelling being inverted for the treatments with emtricitabine and efavirenz in the graph in Fig. 6A. Please see the corrected figure above. We apologize for any inconvenience caused.

AB - It has come to our attention that there was a mistake in Fig. 6 in the published version of our manuscript. The mistake occurred during the publication process and has resulted in the labelling being inverted for the treatments with emtricitabine and efavirenz in the graph in Fig. 6A. Please see the corrected figure above. We apologize for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85100320763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85100320763&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2021.01.003

DO - 10.1016/j.jhep.2021.01.003

M3 - Comment/debate

C2 - 33526292

AN - SCOPUS:85100320763

SN - 0168-8278

VL - 74

SP - 1003

EP - 1004

JO - Journal of Hepatology

JF - Journal of Hepatology

IS - 4

ER -

Gwag T, Meng Z, Sui Y, Helsley RN, Park SH, Wang S et al. Erratum: Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis (Journal of Hepatology (2019) 70(5) (930–940), (S0168827819300297), (10.1016/j.jhep.2018.12.038)). Journal of Hepatology. 2021 Apr;74(4):1003-1004. doi: 10.1016/j.jhep.2021.01.003

Erratum: Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis (Journal of Hepatology (2019) 70(5) (930–940), (S0168827819300297), (10.1016/j.jhep.2018.12.038))

Abstract

Bibliographical note

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this